Department of Colorectal Surgery, The Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang Province, P. R. China.
Hum Vaccin Immunother. 2021 Jun 3;17(6):1555-1567. doi: 10.1080/21645515.2020.1840254. Epub 2021 Jan 11.
Cancer is a worldwide problem that threatens human health. Radiotherapy plays an important role in a variety of cancer treatment methods. The administration of radiotherapy can alter the differentiation pathways and functions of T cells, which in turn improves the immune response of T cells. Radiotherapy can also induce up-regulation of PD-L1 expression, which means that it has great potential for enhancing the therapeutic effect of anti-PD-1/PD-L1 inhibitors and reducing the risk of drug resistance toward them. At present, the combination of radiotherapy and anti-PD-1/PD-L1 inhibitors has shown significant therapeutic effects in clinical tumor research. This review focuses on the mechanism of radiotherapy on T cells reported in recent years, as well as related research progress in the application of PD-1/PD-L1 blockers. It will provide a theoretical basis for the rational clinical application of radiotherapy combined with PD-1/PD-L1 inhibitors.
癌症是威胁人类健康的全球性问题。放射治疗在多种癌症治疗方法中发挥着重要作用。放射治疗可以改变 T 细胞的分化途径和功能，从而提高 T 细胞的免疫反应。放射治疗还可以诱导 PD-L1 表达上调，这意味着它在增强抗 PD-1/PD-L1 抑制剂的治疗效果和降低其耐药风险方面具有巨大潜力。目前，放射治疗联合抗 PD-1/PD-L1 抑制剂在临床肿瘤研究中已显示出显著的治疗效果。本综述重点关注近年来报道的放射治疗对 T 细胞的作用机制，以及 PD-1/PD-L1 阻滞剂的相关应用研究进展。这将为放射治疗联合 PD-1/PD-L1 抑制剂的合理临床应用提供理论依据。
